Aldactone-D

Quick links to important sections

Aldactone-D

Method of action: Diuretic

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aldactone-D

Property Description
Active Ingredients Furosemide, Spironolactone
Form Oral Tablet (Fixed-Dose Combination)
Pharmacological Class Diuretic Combination, Antihypertensive Agent
General Purpose Management of excess fluid and blood pressure support
Origin Synthetic Compound

Aldactone-D: Classification and Identity

Aldactone-D is a prescription drug provided as an oral tablet and officially classified as a diuretic combination and an antihypertensive agent. It functions as a fixed-dose combination (FDC) product, meaning it contains two different synthetic compound active ingredients, Furosemide and Spironolactone, combined into a single unit. This structure is clinically recognized for offering a streamlined approach to patients who require the complementary actions of both a powerful loop diuretic and a potassium-sparing agent simultaneously.

The Composition: Furosemide and Spironolactone

The formulation's efficacy is based on the distinct yet integrated actions of its two active ingredients. Furosemide is a potent Loop diuretic that acts rapidly to increase the removal of salt and water by the kidneys, thus promoting increased diuresis. The other ingredient, Spironolactone, is a Potassium-sparing diuretic and a Mineralocorticoid receptor antagonist. Spironolactone's role is critical in mitigating potential mineral loss and blocking the effects of the hormone aldosterone, which normally signals the body to retain fluid and sodium.

What is the General Therapeutic Purpose?

The general therapeutic purpose of Aldactone-D is to manage states of excess fluid accumulation (edema) and contribute to the regulation of high blood pressure. The combination harnesses the powerful volume reduction achieved by the loop diuretic while simultaneously employing the potassium-sparing action of Spironolactone to mitigate the risk of electrolyte imbalance often associated with Furosemide used alone. This strategic pairing is often used in situations where resistant fluid retention is a concern, ensuring that the necessary powerful fluid reduction is balanced with essential electrolyte stability.

Regulatory References

  1. Furosemide: MedlinePlus Drug Information
  2. NIH Spironolactone Overview

What side effects are possible with Aldactone-D?

Possible Side Effects and Safety Information

The safety profile for Aldactone-D (spironolactone and hydrochlorothiazide) is officially documented by government regulatory bodies and involves a range of adverse reactions, primarily categorized by frequency and system-organ class.

Serious and Clinically Significant Risks

High-level safety cautions involve severe electrolyte imbalances. The drug is associated with hyperkalemia (high blood potassium levels), which can lead to serious cardiac effects. Conversely, imbalances like hyponatremia (low sodium) and hypomagnesemia have also been reported. The product is strictly contraindicated in patients with anuria (no urine production), severe kidney impairment, pre-existing hyperkalemia, and Addison's disease.

Regulatory documents also detail the risk of severe, life-threatening skin reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Rare cases of acute myopia and secondary angle-closure glaucoma have also been documented, requiring immediate attention if vision changes or eye pain occur.

Common and Organ-Specific Adverse Reactions

The adverse reaction profile includes effects on the reproductive and breast tissue systems. Gynecomastia (breast enlargement in males) is a well-documented side effect, which may be related to both the dosage level and the duration of therapy. Other reported effects include menstrual irregularities and postmenopausal bleeding in females, and impotence in males.

Commonly reported reactions involve the nervous and gastrointestinal systems, such as headache, dizziness, drowsiness, nausea, vomiting, stomach cramping, and diarrhea. Due to its mechanism, the medication can also cause hypotension (low blood pressure) and further worsening of renal function, particularly in volume-depleted patients. Required monitoring includes regular checks of serum potassium, other electrolytes, and renal function.

Overdose and Emergency Response

Overdose with the Furosemide/Spironolactone combination is characterized by severe physiological disturbances directly linked to exaggerated diuretic effects, which regulators classify as potentially life-threatening. The documented clinical manifestations are centered on extreme excessive diuresis, leading to rapid dehydration and profound hypovolemia. This volume loss can present clinically as orthostatic hypotension and general weakness.

Severe systemic effects include significant electrolyte depletion and imbalance, such as hyponatremia, hypokalemia, or potentially hyperkalemia, alongside neurological signs like severe mental confusion and lethargy. The regulatory profile also notes specific risks, including an increased potential for vascular thrombosis and embolism in the elderly and the risk of hepatic encephalopathy and coma in patients with liver cirrhosis.

When to Seek Immediate Medical Attention

Regulatory documents state that immediate medical attention must be sought upon suspicion of overdose or if severe symptoms develop. Urgent medical care is required due to the documented risk of circulatory collapse, severe anaphylactic reactions, and potential for irreversible hearing impairment (ototoxicity).

Management is symptomatic and supportive as no specific antidote is known for this combination. Official procedures mandate the urgent correction of all fluid, electrolyte, and acid-base disturbances, often requiring hospital monitoring and continuous observation of serum sodium, potassium, and creatinine levels.

Therapeutic Uses of Aldactone-D

What Aldactone-D Treats: Main Uses and Benefits

The primary role of Aldactone-D (Furosemide/Spironolactone combination) is applied to help ease the overall symptom burden and provides supportive therapeutic benefit across domains where symptoms related to systemic imbalance create noticeable physiological strain. It is commonly used across conditions presenting with acute or disruptive episodes of fluid imbalance.

This medication is generally relevant in clinical settings for managing the symptoms of congestive heart failure (CHF), resistant hypertension, and fluid accumulation secondary to cirrhosis of the liver or kidney disorders (nephrotic syndrome). This combination is applied in addressing the need for fluid loss while supporting the maintenance of essential potassium levels, which helps prevent muscle weakness that symptoms related to systemic imbalance can cause.

“This combination supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.”


Quick Fact: Relief for Severe Edema This combination is often applied in scenarios where fluid accumulation is difficult to manage and supportive symptomatic assistance is needed to control pronounced swelling and ascites (abdominal fluid buildup).


Eligibility and Restrictions for Use

Aldactone-D (Furosemide/Spironolactone) eligibility is strictly defined by regulatory standards, focusing on patient health status and specific populations to prevent serious adverse outcomes. The medicine is primarily authorized for use in adults requiring diuresis for edema related to congestive heart failure or fluid accumulation secondary to hepatic cirrhosis or nephrotic syndrome. It is also approved for treating hypertension in certain patient groups.

Absolute Contraindications (Must Not Use): The medicine is strictly contraindicated in individuals with:

  • Hyperkalemia (high blood potassium levels).
  • Anuria (no urine production) or acute renal insufficiency.
  • Addison's disease.
  • Hepatic coma or pre-coma.
  • Known hypersensitivity to the active ingredients or sulfonamide derivatives.
  • Concomitant use of Eplerenone.

Populations with Restricted Use:

  • Pregnancy and Lactation: Use is not recommended; official labeling advises use only if the potential benefit outweighs documented fetal risks. Breastfeeding should be avoided.
  • Pediatric Patients: Use is restricted, particularly in infants and young children, due to the risk of nephrocalcinosis (kidney deposits).
  • Organ Impairment: Patients with cirrhosis or severe renal impairment must be monitored closely, as these conditions significantly affect the medicine's safe profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Aldactone-D (Furosemide/Spironolactone) based on resulting physiological constraints and alterations to co-administered drug exposure.

Interaction-Related Restrictions and Constraints

Classification Interacting Substance(s) Official Documented Outcome
Formal Contraindication Eplerenone Significant increase in the risk of severe hyperkalemia with the Spironolactone component.
Avoid Concomitant Use Ethacrynic acid Documented risk of potentiation of ototoxicity with the Furosemide component.

Documented Clinically Significant Interactions

Co-administration with ACE Inhibitors or Angiotensin II Receptor Blockers (ARBs) significantly increases the risk of severe hypotension, renal failure, and hyperkalemia. Diuretic components reduce the renal clearance of Lithium, which can result in elevated plasma concentrations and high risk of toxicity. Similarly, Spironolactone has been shown to increase the half-life of Digoxin.

Interaction Type Requirement/Restriction
Timing-Based Rule Administration of Furosemide and Sucralfate must be separated by at least two hours to preserve the diuretic effect.
Substance Restriction Simultaneous use of Potassium Supplements or Potassium-Containing Salt Substitutes is restricted due to the increased risk of hyperkalemia.
Pharmacodynamic Risk Furosemide may increase the ototoxic potential of Aminoglycoside antibiotics.

Population-specific notes state that patients with impaired renal function or hypoproteinemia face increased severity of certain interaction risks, such as ototoxicity or hyperkalemia, as documented in official labeling.

Mechanism of Action

Aldactone-D combines the distinct actions of spironolactone and hydrochlorothiazide to modulate renal processes through two primary mechanisms.

Mineralocorticoid Receptor Antagonism

This domain involves spironolactone, which acts as a competitive antagonist at the mineralocorticoid receptor (MR), primarily localized in the distal convoluted tubule and collecting duct of the kidney. This receptor-mediated signaling blockade prevents the binding and activation by the endogenous hormone, aldosterone. The resulting mechanistic cascade is the suppression of gene expression for proteins that govern sodium reabsorption (like the ENaC channel) and potassium secretion (like the ROMK channel). The physiological consequence is a reduction in the body's retention of sodium and water, which modulates net sodium reabsorption and reduces potassium secretion.


Thiazide Diuretic Action in the Nephron

This domain involves hydrochlorothiazide, which targets the sodium-chloride symporter (NCC) in the distal convoluted tubule. By inhibiting the NCC, the drug blocks a key pathway for electrolyte reabsorption. This immediate effect modifies the molecular steps of sodium and chloride movement, leading to their increased concentration in the tubular fluid and subsequent excretion in the urine. This process induces a physiological adjustment of reduced fluid volume in the circulatory system.

Dosage and Administration Information

Instruction Map: How to use Aldactone-D — Official Administration Guidelines

The administration of the Aldactone-D fixed-dose combination (Furosemide/Spironolactone) is structured by specific instructions governing the route, dosage, and timing.

Administration scope Value
Route of administration Oral administration (film-coated tablet).
Dosing schedule (Adults) The total daily dose typically ranges from one to four tablets of the 50 mg Spironolactone/20 mg Furosemide strength, determined by the patient's therapeutic response. The lowest effective dosage should be utilized.
Timing in relation to meals Must be taken with or immediately after a meal to enhance the consistency of absorption.
Preparation requirements Tablets must be swallowed whole and should not be crushed or chewed.
Age-group administration rules The fixed-dose combination product is not suitable for use in children. Excretion of both components may be slower in older adults.
Missed-dose rules If a scheduled daily dose is taken in the morning, the subsequent doses should remain on schedule; late doses must be skipped if administration approaches the evening.
Special procedural conditions Dosing is not recommended in the evening due to the risk of nocturnal diuresis and associated sleep disruption. The FDC is reserved for use after individual component titration has confirmed the optimal dosage ratio.

Instruction Classifications (High-Level)

Property Value
Administration method type Oral
Frequency pattern Daily, administered once or in divided doses.
Use-context constraints Reserved for use only after individual component titration.

Resulting Procedural Structure

Official step sequence:

  • The total daily dose is established following the required titration with the individual components.
  • The determined dosage (1–4 tablets) is administered by the oral route.
  • The tablets are swallowed whole, taken with or immediately after a meal.
  • Administration must be timed to occur during the day, entirely avoiding the evening.

Connection to the overall use protocol (4 sentences): The instructions establish that this product is a maintenance therapy administered exclusively via the oral route according to a dose determined by prior individual component titration. The protocol mandates a daily schedule that incorporates specific constraints related to food intake and time of day, ensuring consistent absorption and minimizing disruption from the diuretic action. The overall use is structured around achieving the therapeutic goal with the lowest effective dosage while adhering to these established administrative parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aldactone-D

Research has explored the fixed-dose combination of Furosemide and Spironolactone (Aldactone-D) in contexts related to managing fluid retention that may be resistant to a single diuretic. The evidence base is known to include Randomized Controlled Trials (RCTs) and various comparative studies. Research examined the combination's potential application in managing excess fluid while monitoring physiological strain related to mineral imbalance.


Evidence for Fluid Overload in Congestive Heart Failure

Research examined the combination in adults with chronic Congestive Heart Failure (CHF), including elderly individuals. These trials were typically conducted to compare the combination against single-agent treatments or other regimens. Outcomes monitored included changes in standardized clinical scores used to track outcomes reflecting daily functioning or activity level, the frequency of re-hospitalization events, and physical measurements related to cardiac structure and function.

Some trials described patterns observed in the studies related to electrolyte stability and rates of re-hospitalization when compared to single-agent treatments. Long-term effects are not fully established for the fixed-dose product on outcomes such as heart function or overall survival; much of this data is derived from larger trials focusing on the spironolactone component used alongside other therapies.

Studies for Ascites Secondary to Cirrhosis of the Liver

The evidence primarily relies on Randomized Comparative Studies that explored the combination approach against strategies like sequential therapy in populations of adults with cirrhosis and ascites. Key outcomes was evaluated in studies including: the rate of fluid removal (diuresis), the time required for ascites resolution, and the incidence of laboratory abnormalities such as high or low potassium and sodium levels.

Comparative trials reported that the combination approach was associated with shorter measured time intervals related to fluid mobilization when compared to sequential dosing in some populations. However, studies also reported that the combination therapy was associated with shifts in electrolyte levels monitored in the study.

What Research Gaps and Uncertainties Remain

One recognized limitation is that the evidence quality varies across studies when differentiating between the use of the specific fixed-dose combination tablet and the co-administration of the two individual drugs, which may affect the applicability of some trial results. Furthermore, while the short-term fluid management effects are characterized, the follow-up durations were limited in many studies focusing on the combination product.

Key Studies & References Diuretic Resistance (Review focusing on pathophysiology and management, including nephrotic syndrome)

Frequently Asked Questions (FAQ)

Common questions about Aldactone-D (FAQ)


Q: How quickly should I expect to see the effects of Aldactone-D?

This medication is a fixed-dose combination product containing two active ingredients. The Furosemide component is generally fast-acting, typically causing rapid water loss. However, the diuretic effect of the Spironolactone component takes longer to develop, often requiring several days to reach its full therapeutic effect, according to official product information.


Q: Can Aldactone-D be used for fluid retention not related to heart failure?

Official documentation indicates this medication is approved for fluid retention, or edema, associated with specific underlying conditions. These include fluid accumulation secondary to hepatic cirrhosis and nephrotic syndrome, in addition to its use for high blood pressure (hypertension).


Q: Are there any known interactions between Aldactone-D and common pain relievers like ibuprofen?

Official documentation advises caution regarding Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like ibuprofen. Co-administration with NSAIDs carries the documented risk of reduced diuretic effectiveness and increased risk of hyperkalemia (high potassium levels).


Q: Why is potassium monitoring important when taking Aldactone-D?

The Spironolactone ingredient in Aldactone-D can cause hyperkalemia, a condition of having too much potassium in the blood. Due to the potential for serious cardiac effects from high potassium levels, regulatory information specifies that regular monitoring of potassium and other electrolytes is necessary.


Q: Can Aldactone-D be taken with or without food?

According to the official administration instructions, the tablets must be taken with a meal or immediately after a meal. This is advised to help the body absorb the medicine more consistently and enhance its effect.


Q: What should I do if I miss a dose of Aldactone-D?

Regulatory guidance on missed doses advises that if the dose is remembered early, it may be taken. However, if it is near the time of the next scheduled dose, the missed dose should generally be skipped to maintain the schedule. The patient information states that a double dose should not be taken.


Q: Can Aldactone-D make my skin more sensitive to the sun?

Official warnings for the Hydrochlorothiazide component indicate a risk of photosensitivity (increased skin sensitivity to sunlight). Regulatory information advises avoiding excessive sun exposure. Protective measures, such as using sunscreen and wearing protective clothing, are generally recommended during treatment.


Q: How long does the effect of one dose of Aldactone-D last in the body?

Pharmacokinetic data suggests the primary effects of the Spironolactone component persist throughout the day, as its active substances have a half-life ranging from approximately 13 to 17 hours. This duration of effect supports the typical once or twice-daily administration.


Q: Does Aldactone-D cause hair loss or changes in hair texture?

Though not listed as a common side effect, some postmarketing reports have cited hair loss or thinning associated with the use of the Spironolactone component. However, official regulatory documents state the exact frequency or incidence of this reaction is not well established.


Q: Can Aldactone-D affect sleep patterns or cause insomnia?

Regulatory documents list drowsiness as a potential side effect. Furthermore, the dosing instructions advise against taking the dose in the evening to prevent frequent nighttime urination (nocturnal diuresis), which could potentially disrupt sleep.


Q: Are there any specific foods or drinks to avoid while on Aldactone-D?

Official warnings strictly advise limiting foods that are high in potassium, in addition to completely avoiding potassium supplements and potassium-containing salt substitutes. These restrictions are in place to help mitigate the documented risk of developing hyperkalemia (high potassium levels).


Q: Is it normal to feel dizzy or lightheaded when starting Aldactone-D?

According to the official adverse reaction data, dizziness, lightheadedness, and drowsiness are listed as common side effects, particularly when first starting therapy. This is related to the medication’s intended action of lowering blood pressure and reducing overall fluid volume.


Q: Are there any long-term side effects associated with Aldactone-D use?

Long-term use is associated with chronic risks that necessitate regular monitoring, according to official labeling. These risks include the potential for hyperkalemia and the development of gynecomastia (breast tissue enlargement) in males.


Q: Is it safe to drive or operate machinery after taking Aldactone-D?

Official warnings state that due to the potential for side effects like dizziness, drowsiness, and confusion, caution should be exercised regarding activities that require alertness. It is generally advised that individuals avoid driving or operating complex machinery until the effects of the medication on their abilities are known.


Q: Can Aldactone-D be stopped suddenly, or does it require tapering?

Regulatory patient information indicates that abrupt discontinuation of this medication without professional guidance is not advised. Stopping suddenly may lead to a rapid return of fluid accumulation (edema) or elevated blood pressure.


Q: Are there specific symptoms that warrant calling a doctor immediately while taking Aldactone-D?

Serious symptoms, such as those related to severe electrolyte problems (e.g., irregular heartbeat, muscle weakness, confusion), severe blistering rashes, or sudden changes in vision or eye pain, require prompt medical attention according to regulatory guidance.


Q: Can Aldactone-D cause changes in menstrual cycles for women?

Official adverse reaction data lists menstrual irregularities and postmenopausal bleeding as known side effects associated with the Spironolactone component of the medication.


Q: What is the risk of dehydration when taking Aldactone-D?

The drug's strong diuretic action carries a documented risk of fluid loss and volume depletion. Official warnings state that dehydration can occur, particularly in the initial stages of therapy or with higher doses.


Q: Does Aldactone-D cause weight gain or weight loss?

As a potent diuretic, the medication's intended effect is to remove excess water and retained fluid from the body, which typically results in weight loss related to water weight. Weight gain may suggest the medication is not working as expected.


Q: Are there specific vitamins or minerals that should be limited while taking Aldactone-D?

Regulatory warnings specifically advise against the use of potassium supplements and potassium-containing salt substitutes. There is no explicit restriction listed in official documents for other common vitamins or minerals.


Q: Does Aldactone-D affect blood sugar levels?

The Spironolactone component has been associated with potential metabolic disturbances. This includes reports of mild, temporary increases in blood sugar (hyperglycemia), meaning monitoring may be necessary for patients with pre-existing risks.


Q: What are the signs of too much potassium (hyperkalemia) while taking Aldactone-D?

Observable signs of hyperkalemia can include muscle weakness, a tingling or numbness sensation, and feeling confused. If symptoms like an irregular or racing heartbeat occur, prompt medical evaluation is necessary, as this is the most serious sign.


How should Aldactone-D be stored and disposed of?

Official Storage and Disposal Requirements

Scope Item Official Regulatory Statement
Labeled Storage Temperature: Store at Controlled Room Temperature (20^circ to 25 C / 68^circ to 77 F), with excursions permitted to 15^circ to 30 C (59^circ to 86 F) [Source: FDA].
Protection Requirements: Must be protected from light and stored in a dry place [Source: MedlinePlus].
Handling Requirements: Keep the product in the original container and keep from freezing [Source: Mayo Clinic].
Disposal Instructions: Return unused or expired product to a pharmacy or official drug take-back program [Source: FDA].
Child-Protection Storage: Keep out of the sight and reach of children [Source: NIH MedlinePlus].

Official Storage and Disposal Statements: The regulatory documents specify that Aldactone-D tablets must be maintained at Controlled Room Temperature to ensure chemical stability. The medicine must also be protected from light and moisture by being kept in its original, closed container. Proper disposal requires that unused or expired tablets are returned to a designated collection point, with instruction that they must not be flushed down the toilet to protect the environment.

Storage-Context Constraints: Controlled Room Temperature; Protect from Light; Dry place; Keep out of reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aldactone-D found in:

A-Z Index: